Thus, PD1 inhibitors (nivolumab and pembrolizumab) and CTLA4 inhibitors (ipilimumab) enhance anti-tumor immune response delaying tumor growth and facilitating tumor rejection. This evidence concerns the gene CTLA4 and neoplasm.